A recent study published in Ophthalmology has found that a combination of polihexanide (PHMB) and propamidine is a safe and effective treatment for Acanthamoeba keratitis (AK), a rare eye infection that can lead to vision loss.
The study, conducted by John K.G. Dart, D.M. from Moorfields Eye Hospital in London, compared two treatment options for AK: topical PHMB 0.02 percent + propamidine 0.1 percent and PHMB 0.08 percent + placebo. The analysis included 127 patients.
The researchers discovered that both treatment options had high cure rates within 12 months. The adjusted medical cure rate was 86.6 percent for PHMB 0.02 percent + propamidine and 86.7 percent for PHMB 0.08 percent. These results met the noninferiority requirement for PHMB 0.08 percent. Secondary outcomes for both groups were also similar, with a median best-corrected visual acuity of 20/20 and an overall treatment failure rate of 13.4 percent.
Importantly, no serious drug-related adverse events occurred during the study. Dart expressed hope that these findings will improve access and consistency of treatment for AK, addressing the needs of patients.
It is worth noting that several authors involved in the study disclosed ties to pharmaceutical companies, including SIFI S.p.A., which sponsored and funded the trial.
For more information, you can read the abstract and full text of the study here.
Copyright © 2023 HealthDay. All rights reserved.